GBT Pharma, the international development consultancy has secured entry into Latin America for its client Similasan. Similasan has been providing homeopathic remedies for over 30 years. Today they offer over 150 preparations for eye, ear, nose, throat and chest ailments.
Voted ‘most trusted brand’ 11 times by the Swiss Reader’s Digest magazine, Similasan® is developed and produced exclusively in Switzerland.
similasan.jpgWidely available across Switzerland, North America, South Africa, and in parts of Europe, Similasan® set their sights on breaking into major Latin American markets from 2011.
Impressed with GBT Pharma’s track record, the company was appointed as Similasan’s® partner to guide and facilitate this growth plan.
Urs Lehmann, CEO of Similasan® commented:
“Entry into new markets with natural health products is an intricate task. From the outset, GBT Pharma understood our business. Their first-class knowledge of global healthcare markets is clear to see.
“To succeed, you need the right product mix and first-class regulatory expertise is crucial. GBT Pharma ensured we had exactly that, before identifying markets with the highest potential and the right strategy to get us there.
“The recommendations they provided were realistic, practical and a perfect fit for our business, brands and vision.
“In the last 18 months, GBT Pharma has secured new partners for us in Brazil, Mexico, Colombia, Peru and Chile. I would not hesitate in recommending them as a partner in driving your business forward in new territories.”